← back to search

Subhiksha Nandakumar

Stanford University · US
Area of research
Oncology · Pulmonary and Respiratory Medicine
Research interest
Research interests include Prostate Cancer Treatment and Research, Cancer Genomics and Diagnostics, PARP inhibition in cancer therapy, and Cancer Immunotherapy and Biomarkers.
h-index
22
citations
3,544
works
343
NIH funding
primary concept
Medicine
email

Recent publications

BRCA2 reversion mutation–independent resistance to PARP inhibition through impaired DNA prereplication complex function
Proceedings of the National Academy of Sciences 2025cited by 7position: middledoi
Automated real-world data integration improves cancer outcome prediction
Nature 2024cited by 140position: middledoi
Integrative Molecular Analyses of the MD Anderson Prostate Cancer Patient-derived Xenograft (MDA PCa PDX) Series
Clinical Cancer Research 2024cited by 24position: middledoi
A Phase II Study Assessing Long-term Response to Ibrutinib Monotherapy in Recurrent or Refractory CNS Lymphoma
Clinical Cancer Research 2024cited by 20position: middledoi
Real-world experience with circulating tumor DNA in cerebrospinal fluid from patients with central nervous system tumors
Acta Neuropathologica Communications 2024cited by 19position: middledoi
Long-term Outcomes in Primary CNS Lymphoma After R-MVP and High-Dose Chemotherapy With Autologous Hematopoietic Stem Cell Transplant
Neurology 2023cited by 15position: middledoi
Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients
Cell 2022cited by 637position: middledoi
BRCA mutational status shapes the stromal microenvironment of pancreatic cancer linking clusterin expression in cancer associated fibroblasts with HSF1 signaling
Nature Communications 2022cited by 79position: middledoi
The Impact of PIK3R1 Mutations and Insulin–PI3K–Glycolytic Pathway Regulation in Prostate Cancer
Clinical Cancer Research 2022cited by 50position: middledoi
Differences in Prostate Cancer Genomes by Self-reported Race: Contributions of Genetic Ancestry, Modifiable Cancer Risk Factors, and Clinical Factors
Clinical Cancer Research 2021cited by 55position: middledoi
Oncogenic Genomic Alterations, Clinical Phenotypes, and Outcomes in Metastatic Castration-Sensitive Prostate Cancer
Clinical Cancer Research 2020cited by 182position: middledoi
Specific Mutations in APC, but Not Alterations in DNA Damage Response, Associate With Outcomes of Patients With Metastatic Colorectal Cancer
Gastroenterology 2020cited by 84position: middledoi
A Novel Mechanism Driving Poor-Prognosis Prostate Cancer: Overexpression of the DNA Repair Gene, Ribonucleotide Reductase Small Subunit M2 (RRM2)
Clinical Cancer Research 2019cited by 168position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Nikolaus Schultz · Cancer Clinic6 papers (2020–2025)Philip W. Kantoff · Memorial Sloan Kettering Cancer Center4 papers (2019–2022)Wassim Abida · Presbyterian Hospital4 papers (2020–2025)Michael J. Morris · The University of Texas at Austin3 papers (2020–2022)Bastien Nguyen · Eli Lilly (United States)3 papers (2020–2022) · 3 papers (2020–2022)Howard I. Scher · Mayo Clinic Hospital3 papers (2020–2022)Yu Chen · Guangdong Academy of Medical Sciences2 papers (2021–2024)David B. Solit · New York Oncology Hematology2 papers (2020–2021)Goutam Chakraborty · Nanyang Technological University2 papers (2019–2022)Gwo‐Shu Mary Lee · Harvard University2 papers (2019–2022) · 2 papers (2020–2021)Andreas G. Wibmer · New York Oncology Hematology2 papers (2020–2022) · 2 papers (2019–2022)Lorelei A. Mucci · American Cancer Society2 papers (2021–2022)Zahra Khan · University of Birmingham1 papers (2025–2025)Kyrie Pappas · Memorial Sloan Kettering Cancer Center1 papers (2025–2025) · 1 papers (2022–2022)Samuel Haywood · University of Sheffield1 papers (2020–2020)Matthew L. Freedman · Harvard University1 papers (2019–2019)